Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06186973

Fetal Assessment of the Myocardium and Evaluation of the Neonate

FAME-n aims to improve perinatal care by introducing new approaches to fetal and neonatal heart assessment. Better identification of high-risk deliveries requiring intervention will reduce perinatal asphyxia-related illness and death. Neonatal hemodynamics may be improved by early detection of instability of the heart and circulation. Innovative use of technology enables characterization of normal and abnormal cardiovascular transition in a significantly larger number of fetuses and newborn infants than what was previously possible. The methods used may have broad generalizability and applicability in perinatal, neonatal and pediatric medicine.

In September 2023, the project was expanded with an obstetric arm called Epidural analgesia: Fetal Oxygenation and Maternal Oxygenation (Epi-FOMO). In Epi-FOMO, the relationship between maternal breathing and arterial blood gases during labour, and umbilical cord blood gases and neonatal outcomes (as specified in FAME-n) will be investigated.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Among the millions of infants with various degrees of perinatal asphyxia each year, the question how to identify those that without supportive measures will die or develop brain injury remains unanswered. The very small population of infants with severe compromise and requiring advanced delivery room resuscitation and therapeutic hypothermia represents only the tip of the iceberg of infants that die or survive with neurological impairment. Thus, the majority of infants with a poor outcome are difficult to distinguish from those with a healthy survival. This challenge persists because currently used markers of perinatal asphyxia are inadequate and unspecific. Better methods to diagnose and monitor hypoxia-ischemia are called for.

The project will characterize in detail both normal and failed (resulting in perinatal asphyxia) transition from fetal to neonatal life. We will study the fetal/neonatal heart throughout perinatal transition, as a continuum and a single physiological entity. This cross-disciplinary approach is groundbreaking as it challenges current clinical practice, knowledge and research. Innovative use of existing technology contributes to further exploring the heart to provide prognostic information and guide supportive therapy.

The target group is fetuses and newborn infants with mild to moderate perinatal asphyxia, i.e., "uncomplicated" infants at birth that later die or develop brain injury.

Our research question is whether immediate neonatal electrocardiogram (ECG) corresponds to fetal ECG as monitored by cardiotocography (CTG) with ST-segment analysis (STAN), and whether neonatal ECG morphology differentiates between infants with mild to moderate perinatal asphyxia and healthy infants. Umbilical cord blood biomarkers, clinical outcomes and secondarily, cardiac output will be used to answer the research question.

For the Epi-FOMO study arm - maternal blood samples during labor will be drawn from an arterial line. The Epi-FOMO participants are a subset of those included in FAME-n, and we will include an equal number of delivering women with and without epidural analgesia. The hypothesis is that epidural analgesia affects maternal breathing and gas exchange, which in turn affects fetal gas exchange and the condition of the newborn infant. We believe that measurement of amniotic fluid lactate during labor may serve as "proof of concept" that maternal respiration during labor modifies the risk of perinatal asphyxia.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Women admitted for labor and newborn infants will be included after written consent from both parents (if applicable). The final inclusion criterion is that CTG with STAN is used for fetal surveillance at clinician's discretion.

Exclusion criteria

Perinatal asphyxia fulfilling the criteria for therapeutic hypothermia, major malformations and stillbirth, known chromosomal anomalies or congenital heart defects other than a patent ductus arteriosus.

Treatment and study plan

Monitoring with Neobeat heart rate meter

Other

At the designated time for cord clamping as per clinical indication, a 10 cm segment of the umbilical cord will be double-clamped and 5 ml of preferably arterial blood will be obtained.

In infants brought to the resuscitation table, six ECG electrodes will be placed on the skin and cardiac output will be measured with a hemodynamic monitor (PhysioFlow®) for at least 10 min, or until the end of resuscitation/stabilization.

Other names: Umbilical cord blood withdrawal and Monitoring with impedance cardiography

Maternal arterial blood gases

Other

Arterial blood gases will be drawn from a radial artery line and analyzed at the end of a contraction at pre-specified time points during labor.

Amniotic fluid lactate

Other

Amniotic fluid will be collected (2mL) and analyzed at pre-specified time points after rupture of the membranes.

Primary outcomes

  1. Neonatal ECG

    Time frame: From birth until 10 minutes of age

    Blindly categorized neonatal ECG

  2. Cardiac enzymes

    Time frame: At the designated time for cord clamping as per clinical indication

    Umbilical cord blood cardiac enzymes: Creatine kinase (CK)-MB and troponin T

  3. Cardiac output

    Time frame: From birth at least until 10 minutes of age

    Cardiac output

  4. STAN

    Time frame: 10 minutes prior to delivery

    Blindly categorized STAN ECG raw data

Secondary outcomes

  1. Autonomic function

    Time frame: At the designated time for cord clamping as per clinical indication

    Umbilical cord blood metanephrines

Other outcomes

  1. Maternal arterial blood gases

    Time frame: Four times during 1st stage of labor, during pushing and after delivery, maximum duration 24 hours of total labor time

    Oxygen partial pressure (pO2) and carbondioxide partial pressure (pCO2)

  2. Amniotic fluid lactate

    Time frame: Four times during 1st stage of labor, and during pushing, maximum duration 24 hours of total labor time

    Analyzed in 2mL amniotic fluid

Study contacts

Contact information is provided by the study sponsor or research team.

Anne Lee Solevåg, MD, PhD

CONTACT

[email protected]

+4741469314

Kathrine Samuelsen Hansen, MSc

CONTACT

[email protected]

+4791711476

Sponsors and collaborators

Lead sponsor

Oslo University Hospital

Other

Collaborators

  • South-Eastern Norway Regional Health Authority

Registry information

Acronym: FAME-n

Important dates

Study start
2022
Primary completion
2030
Study completion
2035
First posted
Jan 2, 2024
Registry last updated
Mar 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.